One of the most anticipated human longevity studies has finally been published.

The PEARL Trial evaluated weekly low-dose rapamycin in healthy adults over 48 weeks in a randomized, placebo-controlled study.

Key points

• 48-week randomized, placebo-controlled trial
• Weekly low-dose rapamycin
• Primary objective: evaluate long-term safety
• Researchers also assessed body composition and several aging-related biomarkers
• Adds important human safety data for rapamycin use in healthy adults

The study contributes valuable evidence to the ongoing discussion about rapamycin and healthy aging. While the safety findings are encouraging, it's important to note that this trial was not designed to determine whether rapamycin extends human lifespan, and larger, longer-term studies will be needed before firm conclusions can be made about healthspan or longevity benefits.

PubMed ID: 40188830

What do you think this means for the future of longevity research? Could rapamycin become one of the first evidence-based longevity interventions, or is it still too early to tell?

TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

More: https://www.businesswire.com/news/home/20260624119051/en/TRYNGOLZA-olezarsen-approved-by-the-FDA-as-the-first-and-only-treatment-to-reduce-triglycerides-and-the-risk-of-acute-pancreatitis-in-patients-with-severe-hypertriglyceridemia-sHTG